<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02547727</url>
  </required_header>
  <id_info>
    <org_study_id>495/2015</org_study_id>
    <nct_id>NCT02547727</nct_id>
  </id_info>
  <brief_title>Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults</brief_title>
  <official_title>Humoral and Cell-mediated Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in Previously Rabies Immunized HIV-infected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Saovabha Memorial Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen Saovabha Memorial Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A four-site intradermal rabies booster vaccination in HIV - infected patients who have ever
      received primary rabies vaccination could improve their immune response to this kind of
      vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A four-site intradermal rabies booster vaccination has shown higher immune response than
      conventional intramuscular rabies booster vaccination in healthy persons. So, the
      investigators hypothesized the same outcome in HIV - infected patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rabies neutralizing antibody titers</measure>
    <time_frame>Change from baseline of geometric mean titres of rabies neutralizing antibody titres at 2 weeks</time_frame>
    <description>Rabies neutralizing antibody titers would be represented and compared by geometric mean titers (GMTs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specific T cell response</measure>
    <time_frame>Change from baseline of percentages of rabies-antigen specific CD4+ T cells at 2 weeks</time_frame>
    <description>Specific T cell response is measured by OX-40 assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines assessment</measure>
    <time_frame>Change from baseline of cytokines levels at 1 week</time_frame>
    <description>A few cytokines levels are measured by multiplex bead array assay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Rabies</condition>
  <arm_group>
    <arm_group_label>Four-site intradermal vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1 ml of rabies vaccine is distributed to 4 sites over both arms and thigh intradermally on day 0. Blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intramuscular vaccination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5 ml of rabies vaccine is injected to one arm on day 0 and 3.Blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rabies vaccine</intervention_name>
    <description>Rabies vaccine is injected according to the protocol then blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.</description>
    <arm_group_label>Four-site intradermal vaccination</arm_group_label>
    <arm_group_label>Intramuscular vaccination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infected patients

          -  Age 18 - 60 years

          -  Received primary rabies immunization

        Exclusion Criteria:

          -  Have any active opportunistic infections

          -  Received blood or blood product within 3 months

          -  Allergy to vaccine or any vaccine components

          -  Received anti-malarial drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suda Sibunruang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Saovabha Memorial Institute. Faculty of Medicine, Chulalongkorn university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suda Sibunruang, MD</last_name>
    <phone>+66 81 7366076</phone>
    <email>sudapunrin@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Terapong Tantawichien, MD</last_name>
    <phone>+66 81 7350654</phone>
    <email>terapong_tantawichien@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Queen Saovabha Memorial Institute, Thai Red Cross Society</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suda Sibunruang, M.D.</last_name>
      <phone>+66 81 7366076</phone>
      <email>sudapunrin@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Terapong Tantawichien, M.D.</last_name>
      <phone>+66 2 2520161</phone>
      <phone_ext>125</phone_ext>
      <email>queensaovabha@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Suda Sibunruang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2015</study_first_submitted>
  <study_first_submitted_qc>September 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen Saovabha Memorial Institute</investigator_affiliation>
    <investigator_full_name>Suda Sibunruang</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>rabies vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Blocking</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

